

GLOBAL MARKETS FOR TREATMENTS FOR SYNDROMES OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS



PHM118A
October 2012

Shalini Shahani Dewan
Project Analyst

ISBN: 0-89336-132-1

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY OBJECTIVES	1
REASONS FOR DOING THIS STUDY	1
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	1
SCOPE OF THE STUDY	2
METHODOLOGY	2
INFORMATION SOURCES	2
ABOUT THE AUTHOR	2
RELATED BCC RESEARCH REPORTS	3
BCC ON-LINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 EXECUTIVE SUMMARY	5
<i>SUMMARY TABLE GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017 (\$ MILLIONS)</i>	6
CHAPTER 3 OVERVIEW	8
DEFINITIONS	8
NEURONS	8
CENTRAL NERVOUS SYSTEM	8
BRAIN	8
SPINAL CORD	9
NEUROTRANSMITTERS	9
CLASSIFICATION	9
<i>TABLE 1 CLASSIFICATION BY PRIMARY DYSFUNCTION</i>	9
PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS	9
FRIEDREICH'S ATAXIA	10
GERTSMANN-STRAUSSLER-SCHEINKER DISEASE	10
MACHADO-JOSEPH DISEASE	10
AMYOTROPHIC LATERAL SCLEROSIS	11
HEREDITARY SPASTIC PARAPLEGIA	11
HEREDITARY NEUROPATHIES	11
MULTIPLE SCLEROSIS	12
DIAGNOSTIC TESTS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS	12
DIAGNOSTIC TESTS FOR MULTIPLE SCLEROSIS	12
DIAGNOSTIC TESTS FOR AMYOTROPHIC LATERAL SCLEROSIS	12
DIAGNOSTIC TESTS FOR FRIEDREICH'S ATAXIA	13
DIAGNOSTIC TESTS FOR MACHADO-JOSEPH DISEASE	13
DIAGNOSTIC TESTS FOR HEREDITARY SPASTIC PARAPLEGIA	13
DIAGNOSTIC TESTS FOR HEREDITARY NEUROPATHIES	13
CHAPTER 4 REGULATORY ASPECTS	15
DRUG APPROVALS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS	16

TOPIC	PAGE NO.
<i>TABLE 2 ABBREVIATED APPROVALS AND NEW DRUG APPROVALS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2012</i>	16
<i>TABLE 3 NEW DRUG APPLICATIONS FOR THE PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS</i>	17
<i>TABLE 4 SAFETY ALERTS, 2010-MARCH 2012</i>	18
<i>TABLE 5 RECALLS FOR DRUGS USED TO TREAT PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-MARCH 2012</i>	18
REGULATORY DEVELOPMENTS OF PRODUCTS USED TO TREAT PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS	18
CHAPTER 5 NEW DEVELOPMENTS	20
<i>TABLE 6 NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2012</i>	20
<i>TABLE 7 NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011</i>	22
<i>TABLE 8 NEW DEVELOPMENTS IN THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010</i>	26
CHAPTER 6 GLOBAL MARKETS	29
MARKETS BY DYSFUNCTION	29
MARKET OVERVIEW	29
MARKET REVENUE	30
<i>TABLE 9 GLOBAL REVENUES OF DRUG PRODUCTS FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, THROUGH 2017 (\$ MILLIONS)</i>	30
<i>FIGURE 1 GLOBAL REVENUES OF DRUG PRODUCT FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, 2010-2017 (\$ MILLIONS)</i>	30
MARKET SHARE	31
<i>TABLE 10 MARKET SHARE OF DRUGS USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTIONS, 2011 (%)</i>	31
<i>FIGURE 2 MARKET SHARE OF DRUG USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTION, 2011 (%)</i>	31
MARKETS BY DISORDERS	31
MARKET OVERVIEW	32
MARKET REVENUE	33
<i>TABLE 11 GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	34
<i>FIGURE 3 GLOBAL SALES OF DRUG PRODUCT FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017 (\$ MILLIONS)</i>	34
MARKET SHARE	35
<i>TABLE 12 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011 (%)</i>	35
<i>FIGURE 4 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011 (%)</i>	36
MARKET BY REGIONS	36
MARKET OVERVIEW	36
MARKET REVENUE	37
<i>TABLE 13 MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	37
<i>FIGURE 5 MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2010-2017 (\$ MILLIONS)</i>	37
MARKET SHARE	38

TOPIC	PAGE NO.
<i>TABLE 14 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011 (%)</i>	38
<i>FIGURE 6 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011 (%)</i>	38
MARKETS BY TECHNOLOGY	38
MARKET OVERVIEW	39
MARKET REVENUE	40
<i>TABLE 15 GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	40
<i>FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	40
MARKET SHARE	41
<i>TABLE 16 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011 (%)</i>	41
<i>FIGURE 8 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011 (%)</i>	41
CHAPTER 7 PROGRESSIVE ATAXIA SYNDROME MARKET	43
MARKET BY DISEASE TYPE	44
FRIEDREICH'S ATAXIA	44
GERTSMAN-STRAUSSLER-SCHEINKER DISEASE	44
MACHADO-JOSEPH DISEASE	45
MARKET OVERVIEW	46
MARKET REVENUE	46
<i>TABLE 17 SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)</i>	47
<i>FIGURE 9 SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA BY DISEASE TYPE, 2010-2017 (\$ MILLIONS)</i>	47
MARKET SHARE	47
<i>TABLE 18 PROGRESSIVE ATAXIA DRUG MARKET BY DISEASE TYPE, 2011 (%)</i>	48
<i>FIGURE 10 PROGRESSIVE ATAXIA DRUG MARKET BY DISEASE TYPE, 2011 (%)</i>	48
MARKET BY REGION	48
MARKET OVERVIEW	48
MARKET REVENUE	49
<i>TABLE 19 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	49
<i>FIGURE 11 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	49
MARKET SHARE	50
<i>TABLE 20 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2011 (%)</i>	50
<i>FIGURE 12 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2011 (%)</i>	50
Friedreich's Ataxia	51
<i>TABLE 21 FRIEDREICH'S ATAXIA DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	51
<i>FIGURE 13 FRIEDREICH'S ATAXIA DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	51
Gertsmann-Straussler-Scheinker Disease	52
<i>TABLE 22 GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	52
<i>FIGURE 14 GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	52
Machado-Joseph Disease	53
<i>TABLE 23 MACHADO-JOSEPH DISEASE DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	53

TOPIC	PAGE NO.
<i>FIGURE 15 MACHADO-JOSEPH DISEASE DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	54
MARKET BY TECHNOLOGY	54
SMALL MOLECULE	54
MONOCLONAL ANTIBODY	55
OTHER	56
Biomarkers	56
Gene Therapy	57
Stem Cells	57
Other Studies	57
MARKET OVERVIEW	58
MARKET REVENUE	59
<i>TABLE 24 PROGRESSIVE ATAXIA DRUG MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	60
<i>FIGURE 16 PROGRESSIVE ATAXIA DRUG MARKET BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	60
MARKET SHARE	60
<i>TABLE 25 PROGRESSIVE ATAXIA DRUGS SHARE BY TECHNOLOGY, 2011 (%)</i>	61
<i>FIGURE 17 PROGRESSIVE ATAXIA DRUGS SHARE BY TECHNOLOGY, 2011 (%)</i>	61
INDUSTRY STRUCTURE	61
FRIEDREICH'S ATAXIA	62
<i>TABLE 26 LEADING MANUFACTURERS AND SUPPLIERS OF FRIEDREICH'S ATAXIA DRUGS AND THERAPIES</i>	62
<i>TABLE 27 MARKET SHARES FOR MANUFACTURERS AND DISTRIBUTORS OF FRIEDREICH'S ATAXIA DRUGS, 2011 (%)</i>	63
<i>FIGURE 18 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF FRIEDREICH'S ATAXIA DRUGS, 2011 (%)</i>	63
GERSTMANN-STRAUSSLER-SCHEINKER DISEASE	64
<i>TABLE 28 LEADING MANUFACTURERS AND SUPPLIERS OF GERSTMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS AND THERAPIES</i>	64
<i>TABLE 29 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF GERSTMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS, 2011 (%)</i>	66
<i>FIGURE 19 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF GERSTMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS, 2011 (%)</i>	66
MACHADO-JOSEPH DISEASE	67
<i>TABLE 30 LEADING MANUFACTURERS AND SUPPLIERS OF MACHADO-JOSEPH DISEASE DRUGS AND THERAPIES</i>	67
<i>TABLE 31 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MACHADO-JOSEPH DISEASE DRUGS, 2011 (%)</i>	68
<i>FIGURE 20 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MACHADO-JOSEPH DISEASE DRUGS, 2011 (%)</i>	69
CHAPTER 8 PROGRESSIVE WEAKNESS SYNDROME MARKETS	71
MARKET BY DISEASE TYPE	71
AMYOTROPHIC LATERAL SCLEROSIS	71
PROGRESSIVE BULBAR PALSY	73
HEREDITARY SPASTIC PARAPLEGIA	74
HEREDITARY NEUROPATHIES	75
MULTIPLE SCLEROSIS	76
MARKET OVERVIEW	77
<i>TABLE 32 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)</i>	78

TOPIC	PAGE NO.
<i>FIGURE 21 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY DISEASE TYPE, 2010-2017 (\$ MILLIONS)</i>	78
MARKET SHARE	79
<i>TABLE 33 PROGRESSIVE WEAKNESS DRUG MARKET BY DISEASE TYPE, 2011 (%)</i>	80
<i>FIGURE 22 PROGRESSIVE WEAKNESS DRUG MARKET BY DISEASE TYPE, 2011 (%)</i>	80
MARKETS BY REGION	80
MARKET OVERVIEW	81
MARKET REVENUE	81
<i>TABLE 34 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	82
<i>FIGURE 23 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	82
MARKET SHARE	82
<i>TABLE 35 PROGRESSIVE WEAKNESS DRUG MARKET BY REGION, 2011 (%)</i>	83
<i>FIGURE 24 PROGRESSIVE WEAKNESS DRUG MARKET BY REGION, 2011 (%)</i>	83
Amyotrophic Lateral Sclerosis	83
<i>TABLE 36 AMYOTROPHIC LATERAL SCLEROSIS DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	84
<i>FIGURE 25 AMYOTROPHIC LATERAL SCLEROSIS DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	84
Progressive Bulbar Palsy	84
<i>TABLE 37 PROGRESSIVE BULBAR PALSY DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	85
<i>FIGURE 26 PROGRESSIVE BULBAR PALSY DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	85
Hereditary Spastic Paraplegia	85
<i>TABLE 38 HEREDITARY SPASTIC PARAPLEGIA DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	86
<i>FIGURE 27 HEREDITARY SPASTIC PARAPLEGIA DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	86
Hereditary Neuropathies	86
<i>TABLE 39 HEREDITARY NEUROPATHY DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	87
<i>FIGURE 28 HEREDITARY NEUROPATHY DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	87
Multiple Sclerosis	87
<i>TABLE 40 MULTIPLE SCLEROSIS DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	88
<i>FIGURE 29 MULTIPLE SCLEROSIS DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)</i>	88
MARKET BY TECHNOLOGY	88
PROGRESSIVE WEAKNESS SYNDROME AND ITS EFFECT ON THE BRAIN AND SPINAL CORD	88
Small Molecules	89
Monoclonal Antibody	90
Other	90
Biomarkers	91
Gene Therapy	91
Stem Cells	92
Market Overview	94
Market Revenue	95
<i>TABLE 41 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	95

TOPIC	PAGE NO.
<i>FIGURE 30 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	95
Market Share	96
<i>TABLE 42 PROGRESSIVE WEAKNESS MARKET BY TECHNOLOGY, 2011 (%)</i>	96
<i>FIGURE 31 PROGRESSIVE WEAKNESS MARKET BY TECHNOLOGY, 2011 (%)</i>	96
MULTIPLE SCLEROSIS	97
Small Molecule	97
Monoclonal Antibody	98
Other	98
Biomarkers	98
Gene Therapy	99
Stem Cells	99
Market Overview	100
Market Revenue	101
<i>TABLE 43 MULTIPLE SCLEROSIS DRUG MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	101
<i>FIGURE 32 MULTIPLE SCLEROSIS DRUG MARKET BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	101
Market Share	102
<i>TABLE 44 MULTIPLE SCLEROSIS DRUG MARKET DISTRIBUTION BY TECHNOLOGY, 2011 (%)</i>	102
<i>FIGURE 33 MULTIPLE SCLEROSIS DRUG MARKET DISTRIBUTION BY TECHNOLOGY, 2011 (%)</i>	102
INDUSTRY STRUCTURE	102
AMYOTROPHIC LATERAL SCLEROSIS	103
<i>TABLE 45 LEADING MANUFACTURERS AND SUPPLIERS OF DRUGS AND THERAPIES FOR AMYOTROPHIC LATERAL SCLEROSIS</i>	103
<i>TABLE 46 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS AMYOTROPHIC LATERAL SCLEROSIS DRUGS, 2011 (%)</i>	105
<i>FIGURE 34 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF AMYOTROPHIC LATERAL SCLEROSIS DRUGS, 2011 (%)</i>	106
PROGRESSIVE BULBAR PALSY	106
<i>TABLE 47 LEADING MANUFACTURERS AND SUPPLIERS OF PROGRESSIVE BULBAR PALSY DRUGS AND THERAPIES</i>	106
<i>TABLE 48 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF PROGRESSIVE BULBAR PALSY DRUGS, 2011 (%)</i>	108
<i>FIGURE 35 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF PROGRESSIVE BULBAR PALSY DRUGS, 2011 (%)</i>	108
HEREDITARY SPASTIC PARAPLEGIA	109
<i>TABLE 49 LEADING MANUFACTURERS AND SUPPLIERS OF HEREDITARY SPASTIC PARAPLEGIA DRUGS AND THERAPIES</i>	109
<i>TABLE 50 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY SPASTIC PARAPLEGIA DRUGS, 2011 (%)</i>	111
<i>FIGURE 36 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY SPASTIC PARAPLEGIA DRUGS, 2011 (%)</i>	111
HEREDITARY NEUROPATHIES	112
<i>TABLE 51 LEADING MANUFACTURERS AND SUPPLIERS OF HEREDITARY NEUROPATHY DRUGS AND THERAPIES</i>	112
<i>TABLE 52 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY NEUROPATHIES DRUGS, 2011 (%)</i>	114
<i>FIGURE 37 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY NEUROPATHY DRUGS, 2011 (%)</i>	115
MULTIPLE SCLEROSIS	115

TOPIC	PAGE NO.
<i>TABLE 53 LEADING MANUFACTURERS AND SUPPLIERS MULTIPLE SCLEROSIS DRUGS AND THERAPIES</i>	115
<i>TABLE 54 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MULTIPLE SCLEROSIS DRUGS, 2011 (%)</i>	117
<i>FIGURE 38 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MULTIPLE SCLEROSIS, DRUGS 2011 (%)</i>	118
CHAPTER 9 PATENT ANALYSIS	120
PATENTS BY YEAR	121
<i>TABLE 55 TOTAL NUMBER OF PATENTS BY YEAR, 2010-MARCH 2012</i>	121
<i>FIGURE 39 NUMBER OF PATENTS BY YEAR, 2010-MARCH 2012</i>	121
PATENTS BY DISEASE CATEGORY	121
<i>TABLE 56 PATENTS BY DISEASE CATEGORY, 2010-MARCH 2012</i>	122
<i>FIGURE 40 PATENTS BY DISEASE CATEGORY, 2010-MARCH 2012</i>	122
PATENTS BY DISEASE TYPE	122
PROGRESSIVE ATAXIA SYNDROMES	122
<i>TABLE 57 PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE, 2010-2012</i>	123
<i>FIGURE 41 PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE, 2010-2012</i>	123
PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD	123
<i>TABLE 58 PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT THE ON BRAIN AND SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010-2012</i>	124
<i>FIGURE 42 PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON BRAIN AND SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010-2012</i>	124
PATENTS BY COUNTRY	124
PROGRESSIVE ATAXIA SYNDROMES	124
<i>TABLE 59 U.S. PATENTS BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES, 2010-2012</i>	125
<i>TABLE 60 PATENT SHARES BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES, 2010-2012 (%)</i>	125
PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES	125
<i>TABLE 61 U.S. PATENTS BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES, 2010-2012</i>	126
<i>TABLE 62 PATENT SHARES BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES, 2010-2012 (NO./%)</i>	127
PATENTS BY COMPANY	127
PROGRESSIVE ATAXIA SYNDROMES	127
<i>TABLE 63 U.S. PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY COMPANY, 2010-2012</i>	128
PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES	128
<i>TABLE 64 U.S. PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES BY COMPANY, 2010-2012</i>	129
PATENTS BY ASSIGNEE	131
PROGRESSIVE ATAXIA SYNDROMES	131
<i>TABLE 65 PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY ASSIGNEE, 2010-2012</i>	131
PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES	132
<i>TABLE 66 PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES BY ASSIGNEE, 2010-2012</i>	132
CHAPTER 10 CURRENT SITUATION	134

TOPIC	PAGE NO.
MARKET TRENDS	134
PROGRESSIVE ATAXIAS SYNDROMES	134
Market Drivers	135
PROGRESSIVE WEAKNESS AND EFFECT IN THE BRAIN AND SPINAL CORD SYNDROMES	135
Market Drivers	136
ADDITIONAL DRIVERS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS DRUG MARKET	136
FACTORS GOVERNING THE MARKET	137
COLLABORATIONS, MERGERS AND ACQUISITIONS	137
CHAPTER 11 COMPANY PROFILES	141
ABBOTT LABORATORIES	141
ACORDA THERAPEUTICS INC.	142
ACTAVIS ELIZABETH	142
ALLON THERAPEUTICS INC	143
AMERICAN REGENT INC.	143
APOTEX INC.	144
APOTHECA, INC.	144
APP PHARMACEUTICALS	145
ASTELLAS PHARMA INC.	145
ASTRAZENECA GMBH	146
AUROBINDO PHARMA LTD	146
BAXTER INTERNATIONAL INC.	147
BIOGEN IDEC	147
BOEHRINGER INGELHEIM LTD.	148
BRISTOL-MYERS SQUIBB	148
BRYANT RANCH PREPACK	149
CADILA HEALTHCARE LTD.	149
CARACO PHARMACEUTICAL LABORATORIES	150
CARDINAL HEALTH	150
COGNITION PHARMACEUTICALS LLC	151
CSL BEHRING	151
DR. REDDY'S LABORATORIES LIMITED	152
EISAI CO. LTD	152
ELAN PHARMA INTERNATIONAL LIMITED	153
ELI LILLY AND COMPANY	153
EMD MILLIPORE HEADQUARTERS	154
ENDO PHARMACEUTICALS INC	154
GLAXOSMITHKLINE PLC.	155
GLENMARK GENERICS LIMITED	155
H. LUNDBECK A/S	156
HAMELN PHARMACEUTICALS LTD	156
HOSPIRA INC.	157
INTELLECT NEUROSCIENCES INC.	157
JAZZ PHARMACEUTICALS PLC.	158
LEXICON PHARMACEUTICALS INC.	158
MAJOR PHARMACEUTICALS	159

TOPIC	PAGE NO.
MERCK SERONO	159
MERCK SHARP & DOHME LIMITED	160
MERZ PHARMA GMBH & CO KGAA	160
MOMENTA PHARMACEUTICALS	161
MYLAN PHARMACEUTICALS	161
NEUREN PHARMACEUTICALS LTD.	162
NEUROSEARCH A/S	162
NOSCIRA, S.A.	163
NOVARTIS AG	163
ORCHID CHEMICALS & PHARMACEUTICALS LTD.	164
ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.	164
PAR PHARMACEUTICALS	165
PERRIGO COMPANY	165
PFIZER INC.	166
PHARNEXT	166
PHYSICIANS TOTAL CARE, INC.	167
PLIVA HRVATSKA D.O.O.	167
PROMETHEUS	168
RANBAXY LABORATORIES LIMITED	168
ROCHE HOLDING LTD	169
ROXANE LABORATORIES INC.	169
SANDOZ INTERNATIONAL GMBH	170
SANOFI	170
SANTHERA PHARMACEUTICALS	171
SHIONOGI & CO.	171
SUN PHARMA	172
TAJ PHARMACEUTICALS LIMITED	172
TAKEDA PHARMACEUTICAL COMPANY LIMITED	173
TERCICA, INC	173
TEVA PHARMACEUTICAL INDUSTRIES LTD	174
TORRENT PHARMA	175
UCB S.A.	175
UDL LABORATORIES	175
UPSHER-SMITH LABORATORIES	176
WATSON PHARMACEUTICALS INC.	176
WEST-WARD PHARMACEUTICAL	177
CHAPTER 12 APPENDIX I: ABBREVIATIONS	179

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 CLASSIFICATION BY PRIMARY DYSFUNCTION	9
TABLE 2 ABBREVIATED APPROVALS AND NEW DRUG APPROVALS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2012	16
TABLE 3 NEW DRUG APPLICATIONS FOR THE PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS	17
TABLE 4 SAFETY ALERTS, 2010-MARCH 2012	18
TABLE 5 RECALLS FOR DRUGS USED TO TREAT PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-MARCH 2012	18
TABLE 6 NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2012	20
TABLE 7 NEW DEVELOPMENTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011	22
TABLE 8 NEW DEVELOPMENTS IN THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010	26
TABLE 9 GLOBAL REVENUES OF DRUG PRODUCTS FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, THROUGH 2017 (\$ MILLIONS)	30
TABLE 10 MARKET SHARE OF DRUGS USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTIONS, 2011 (%)	31
TABLE 11 GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017 (\$ MILLIONS)	34
TABLE 12 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011 (%)	35
TABLE 13 MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, THROUGH 2017 (\$ MILLIONS)	37
TABLE 14 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011 (%)	38
TABLE 15 GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	40
TABLE 16 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011 (%)	41
TABLE 17 SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)	47
TABLE 18 PROGRESSIVE ATAXIA DRUG MARKET BY DISEASE TYPE, 2011 (%)	48
TABLE 19 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	49
TABLE 20 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2011 (%)	50
TABLE 21 FRIEDREICH'S ATAXIA DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	51
TABLE 22 GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	52
TABLE 23 MACHADO-JOSEPH DISEASE DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	53
TABLE 24 PROGRESSIVE ATAXIA DRUG MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	60
TABLE 25 PROGRESSIVE ATAXIA DRUGS SHARE BY TECHNOLOGY, 2011 (%)	61
TABLE 26 LEADING MANUFACTURERS AND SUPPLIERS OF FRIEDREICH'S ATAXIA DRUGS AND THERAPIES	62
TABLE 27 MARKET SHARES FOR MANUFACTURERS AND DISTRIBUTORS OF FRIEDREICH'S ATAXIA DRUGS, 2011 (%)	63
TABLE 28 LEADING MANUFACTURERS AND SUPPLIERS OF GERSTMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS AND THERAPIES	64

TABLE HEADING	PAGE NO.
TABLE 29 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS, 2011 (%)	66
TABLE 30 LEADING MANUFACTURERS AND SUPPLIERS OF MACHADO-JOSEPH DISEASE DRUGS AND THERAPIES	67
TABLE 31 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MACHADO-JOSEPH DISEASE DRUGS, 2011 (%)	68
TABLE 32 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)	78
TABLE 33 PROGRESSIVE WEAKNESS DRUG MARKET BY DISEASE TYPE, 2011 (%)	80
TABLE 34 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	82
TABLE 35 PROGRESSIVE WEAKNESS DRUG MARKET BY REGION, 2011 (%)	83
TABLE 36 AMYOTROPHIC LATERAL SCLEROSIS DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	84
TABLE 37 PROGRESSIVE BULBAR PALSY DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	85
TABLE 38 HEREDITARY SPASTIC PARAPLEGIA DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	86
TABLE 39 HEREDITARY NEUROPATHY DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	87
TABLE 40 MULTIPLE SCLEROSIS DRUG MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	88
TABLE 41 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	95
TABLE 42 PROGRESSIVE WEAKNESS MARKET BY TECHNOLOGY, 2011 (%)	96
TABLE 43 MULTIPLE SCLEROSIS DRUG MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	101
TABLE 44 MULTIPLE SCLEROSIS DRUG MARKET DISTRIBUTION BY TECHNOLOGY, 2011 (%)	102
TABLE 45 LEADING MANUFACTURERS AND SUPPLIERS OF DRUGS AND THERAPIES FOR AMYOTROPHIC LATERAL SCLEROSIS	103
TABLE 46 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS AMYOTROPHIC LATERAL SCLEROSIS DRUGS, 2011 (%)	105
TABLE 47 LEADING MANUFACTURERS AND SUPPLIERS OF PROGRESSIVE BULBAR PALSY DRUGS AND THERAPIES	106
TABLE 48 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF PROGRESSIVE BULBAR PALSY DRUGS, 2011 (%)	108
TABLE 49 LEADING MANUFACTURERS AND SUPPLIERS OF HEREDITARY SPASTIC PARAPLEGIA DRUGS AND THERAPIES	109
TABLE 50 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY SPASTIC PARAPLEGIA DRUGS, 2011 (%)	111
TABLE 51 LEADING MANUFACTURERS AND SUPPLIERS OF HEREDITARY NEUROPATHY DRUGS AND THERAPIES	112
TABLE 52 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY NEUROPATHIES DRUGS, 2011 (%)	114
TABLE 53 LEADING MANUFACTURERS AND SUPPLIERS MULTIPLE SCLEROSIS DRUGS AND THERAPIES	115
TABLE 54 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MULTIPLE SCLEROSIS DRUGS, 2011 (%)	117
TABLE 55 TOTAL NUMBER OF PATENTS BY YEAR, 2010-MARCH 2012	121
TABLE 56 PATENTS BY DISEASE CATEGORY, 2010-MARCH 2012	122
TABLE 57 PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE, 2010-2012	123
TABLE 58 PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT THE ON BRAIN AND SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010-2012	124

TABLE HEADING	PAGE NO.
TABLE 59 U.S. PATENTS BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES, 2010-2012	125
TABLE 60 PATENT SHARES BY COUNTRY FOR PROGRESSIVE ATAXIA SYNDROMES, 2010-2012 (%)	125
TABLE 61 U.S. PATENTS BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES, 2010-2012	126
TABLE 62 PATENT SHARES BY COUNTRY FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES, 2010-2012 (NO./%)	127
TABLE 63 U.S. PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY COMPANY, 2010-2012	128
TABLE 64 U.S. PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES BY COMPANY, 2010-2012	129
TABLE 65 PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY ASSIGNEE, 2010-2012	131
TABLE 66 PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON THE BRAIN AND SPINAL CORD SYNDROMES BY ASSIGNEE, 2010-2012	132

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017 (\$ MILLIONS)	6
FIGURE 1 GLOBAL REVENUES OF DRUG PRODUCT FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, 2010-2017 (\$ MILLIONS)	30
FIGURE 2 MARKET SHARE OF DRUG USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTION, 2011 (%)	31
FIGURE 3 GLOBAL SALES OF DRUG PRODUCT FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017 (\$ MILLIONS)	34
FIGURE 4 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2011 (%)	36
FIGURE 5 MARKET FOR DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2010-2017 (\$ MILLIONS)	37
FIGURE 6 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY REGION, 2011 (%)	38
FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	40
FIGURE 8 MARKET SHARE OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS BY TECHNOLOGY, 2011 (%)	41
FIGURE 9 SALES OF DRUG PRODUCTS FOR THE TREATMENT OF PROGRESSIVE ATAXIA BY DISEASE TYPE, 2010-2017 (\$ MILLIONS)	47
FIGURE 10 PROGRESSIVE ATAXIA DRUG MARKET BY DISEASE TYPE, 2011 (%)	48
FIGURE 11 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	49
FIGURE 12 PROGRESSIVE ATAXIA DRUG MARKET BY REGION, 2011 (%)	50
FIGURE 13 FRIEDREICH'S ATAXIA DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	51
FIGURE 14 GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	52
FIGURE 15 MACHADO-JOSEPH DISEASE DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	54
FIGURE 16 PROGRESSIVE ATAXIA DRUG MARKET BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	60
FIGURE 17 PROGRESSIVE ATAXIA DRUGS SHARE BY TECHNOLOGY, 2011 (%)	61
FIGURE 18 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF FRIEDREICH'S ATAXIA DRUGS, 2011 (%)	63
FIGURE 19 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF GERTSMANN-STRAUSSLER-SCHEINKER DISEASE DRUGS, 2011 (%)	66
FIGURE 20 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MACHADO-JOSEPH DISEASE DRUGS, 2011 (%)	69
FIGURE 21 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY DISEASE TYPE, 2010-2017 (\$ MILLIONS)	78
FIGURE 22 PROGRESSIVE WEAKNESS DRUG MARKET BY DISEASE TYPE, 2011 (%)	80
FIGURE 23 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	82
FIGURE 24 PROGRESSIVE WEAKNESS DRUG MARKET BY REGION, 2011 (%)	83
FIGURE 25 AMYOTROPHIC LATERAL SCLEROSIS DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	84
FIGURE 26 PROGRESSIVE BULBAR PALSY DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	85
FIGURE 27 HEREDITARY SPASTIC PARAPLEGIA DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	86
FIGURE 28 HEREDITARY NEUROPATHY DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	87
FIGURE 29 MULTIPLE SCLEROSIS DRUG MARKET BY REGION, 2010-2017 (\$ MILLIONS)	88
FIGURE 30 PROGRESSIVE WEAKNESS SYNDROME DRUG MARKET BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	95

FIGURE TITLE	PAGE NO.
FIGURE 31 PROGRESSIVE WEAKNESS MARKET BY TECHNOLOGY, 2011 (%)	96
FIGURE 32 MULTIPLE SCLEROSIS DRUG MARKET BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	101
FIGURE 33 MULTIPLE SCLEROSIS DRUG MARKET DISTRIBUTION BY TECHNOLOGY, 2011 (%)	102
FIGURE 34 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF AMYOTROPHIC LATERAL SCLEROSIS DRUGS, 2011 (%)	106
FIGURE 35 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF PROGRESSIVE BULBAR PALSY DRUGS, 2011 (%)	108
FIGURE 36 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY SPASTIC PARAPLEGIA DRUGS, 2011 (%)	111
FIGURE 37 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF HEREDITARY NEUROPATHY DRUGS, 2011 (%)	115
FIGURE 38 MARKET SHARES OF MANUFACTURERS AND DISTRIBUTORS OF MULTIPLE SCLEROSIS, DRUGS 2011 (%)	118
FIGURE 39 NUMBER OF PATENTS BY YEAR, 2010-MARCH 2012	121
FIGURE 40 PATENTS BY DISEASE CATEGORY, 2010-MARCH 2012	122
FIGURE 41 PATENTS FOR PROGRESSIVE ATAXIA SYNDROMES BY DISEASE TYPE, 2010-2012	123
FIGURE 42 PATENTS FOR PROGRESSIVE WEAKNESS AND EFFECT ON BRAIN AND SPINAL CORD SYNDROMES BY DISEASE TYPE, 2010-2012	124